GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » Days Sales Outstanding

Truscreen Group (NZSE:TRU) Days Sales Outstanding : 40.58 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group Days Sales Outstanding?

Truscreen Group's average Accounts Receivable for the six months ended in Sep. 2023 was NZ$0.22 Mil. Truscreen Group's Revenue for the six months ended in Sep. 2023 was NZ$0.99 Mil. Hence, Truscreen Group's Days Sales Outstanding for the six months ended in Sep. 2023 was 40.58.

The historical rank and industry rank for Truscreen Group's Days Sales Outstanding or its related term are showing as below:

NZSE:TRU' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.47   Med: 59.82   Max: 635.27
Current: 53.37

During the past 9 years, Truscreen Group's highest Days Sales Outstanding was 635.27. The lowest was 34.47. And the median was 59.82.

NZSE:TRU's Days Sales Outstanding is ranked better than
65.76% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 65.13 vs NZSE:TRU: 53.37

Truscreen Group's Days Sales Outstanding declined from Sep. 2022 (83.11) to Sep. 2023 (40.58).


Truscreen Group Days Sales Outstanding Historical Data

The historical data trend for Truscreen Group's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Truscreen Group Days Sales Outstanding Chart

Truscreen Group Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only 36.83 41.80 34.47 59.82 48.83

Truscreen Group Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.13 121.57 83.11 56.25 40.58

Competitive Comparison of Truscreen Group's Days Sales Outstanding

For the Medical Devices subindustry, Truscreen Group's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Truscreen Group's Days Sales Outstanding Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Truscreen Group's Days Sales Outstanding falls into.



Truscreen Group Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Truscreen Group's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

Days Sales Outstanding (A: Mar. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )*Days in Period
=( (0.275 + 0.17) / 2 ) / 1.663*365
=0.2225 / 1.663*365
=48.83

Truscreen Group's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( (0.17 + 0.268) / 2 ) / 0.985*365 / 2
=0.219 / 0.985*365 / 2
=40.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Truscreen Group  (NZSE:TRU) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Truscreen Group Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Truscreen Group's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Truscreen Group (NZSE:TRU) Business Description

Traded in Other Exchanges
Address
C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is engaged in providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. The company holds a right to the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. Its product, Truscreen utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The company operates its business in New Zealand, Mexico, China, Russia, Iran, Turkey and others. It has one operating segment, it owns the rights to the Truscreen Cervical Cancer screening device.